pharmaphorum

JANUARY 30, 2022

2021 was a record year for investments in UK biotech companies, consolidating the country’s position as one of Europe’s top life science hubs and apparently shrugging off the effects of the pandemic and Brexit. All told, the sector raised £4.5 billion ($6 billion) in public and private financings during the year, almost two-third (60%) up on the previous year, with £1.3 billion coming from initial public offerings (IPOs) on both sides of the Atlantic.

Vaccines 98

Vaccines 98

Fierce Healthcare

JANUARY 30, 2022

Komodo Health notches another major partnership as it gears up to go public. hlandi. Sun, 01/30/2022 - 18:16.

98

98

Pharma Mirror

JANUARY 30, 2022

This type of therapy is often offered by a licensed physical therapist who specializes specifically in young children and babies. It aims at improving a child’s mobility after an injury or illness. You can get these services at home, a daycare center, school, or an outpatient clinic. Typically, the treatment should be provided in a setting that the child feels comfortable.

52

52

pharmaphorum

JANUARY 30, 2022

The FDA has approved Roche’s much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron’s market leading drug Eylea. The US regulator has given the green light to the bispecific antibody – now called Vabysmo – for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema (DME).

FDA 52

FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Mirror

JANUARY 30, 2022

Ben Beckley, Global Lead at EmerGENE explores the market challenges holding back Cell and Gene Therapy (C&GT) from taking its place as an established treatment area. He explains how we can navigate obstacles to ensure C&GT can achieve its full potential. As a treatment area, C&GT has shown robust growth in recent years. Some 3,366 treatments are currently in preclinical and clinical development[1].

52

52

Med Ed 101

JANUARY 30, 2022

I have had a fair number of consults from providers who are referring patients who would like to take supplements or are currently taking supplements. In my humble opinion, no healthcare professional is more educated than a pharmacist to handle addressing whether a supplement is likely to be safe or not. Even if I have […]. The post Which Supplement Should I Take?

40

40